The impact of anticoagulation therapy on kidney function in patients with atrial fibrillation and chronic kidney disease

References

• Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498. doi: 10.1093/eurheartj/ehaa612
   PubMed Web of Science ®Google Scholar
• Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: a review. JAMA. 2019;322(13):1294–1304. doi: 10.1001/jama.2019.14745
   PubMed Web of Science ®Google Scholar
• Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl. 2022;12(1):7–11. doi: 10.1016/j.kisu.2021.11.003
   PubMed Web of Science ®Google Scholar
• Gadde S, Kalluru R, Cherukuri SP, et al. Atrial fibrillation in chronic kidney disease: an overview. Cureus. 2022;14(8):e27753. doi: 10.7759/cureus.27753
   PubMed Web of Science ®Google Scholar
• Hung TW, Huang JY, Jong GP, et al. Long-term outcomes of dialysis in patients with chronic kidney disease and new-onset atrial fibrillation: a population-based cohort study. PLoS One. 2019;14(9):e0222656. doi: 10.1371/journal.pone.0222656
   PubMed Web of Science ®Google Scholar
• Siragy HM, Carey RM. Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. Am J Nephrol. 2010;31(6):541–550. doi: 10.1159/000313363
   PubMed Web of Science ®Google Scholar
• Kulkarni N, Gukathasan N, Sartori S, et al. Chronic kidney disease and atrial fibrillation: a contemporary overview. J Atr Fibrillation. 2012;5(1):448. doi: 10.4022/jafib.448
   PubMedGoogle Scholar
• Schlaich MP, Socratous F, Hennebry S, et al. Sympathetic activation in chronic renal failure. J Am Soc Nephrol. 2009;20(5):933–939. doi: 10.1681/ASN.2008040402
   PubMed Web of Science ®Google Scholar
• Beretta-Piccoli C, Weidmann P, Schiffl H, et al. Enhanced cardiovascular pressor reactivity to norepinephrine in mild renal parenchymal disease. Kidney Int. 1982;22(3):297–303. doi: 10.1038/ki.1982.169
   PubMed Web of Science ®Google Scholar
• Ishii M, Ikeda T, Takagi M, et al. Elevated plasma catecholamines in hypertensives with primary glomerular diseases. Hypertension. 1983;5(4):545–551. doi: 10.1161/01.HYP.5.4.545
   PubMed Web of Science ®Google Scholar
• Symplicity HTNI, Esler MD, Krum H, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the symplicity HTN-2 trial): a randomised controlled trial. Lancet. 2010;376(9756):1903–1909.
   PubMed Web of Science ®Google Scholar
• Genovesi S, Pogliani D, Faini A, et al. Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients. Am J Kidney Dis. 2005;46(5):897–902. doi: 10.1053/j.ajkd.2005.07.044
   PubMed Web of Science ®Google Scholar
• Ananthapanyasut W, Napan S, Rudolph EH, et al. Prevalence of atrial fibrillation and its predictors in nondialysis patients with chronic kidney disease. Clin J Am Soc Nephrol. 2010;5(2):173–181. doi: 10.2215/CJN.03170509
   PubMed Web of Science ®Google Scholar
• Collins AJ, Foley RN, Gilbertson DT, et al. United States renal data System public health surveillance of chronic kidney disease and end-stage renal disease. Kidney Int Suppl. 2015;5(1):2–7. doi: 10.1038/kisup.2015.2
   PubMed Web of Science ®Google Scholar
• Wizemann V, Tong L, Satayathum S, et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int. 2010;77(12):1098–1106. doi: 10.1038/ki.2009.477
   PubMed Web of Science ®Google Scholar
• Go AS, Fang MC, Udaltsova N, et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation. 2009;119(10):1363–1369. doi: 10.1161/CIRCULATIONAHA.108.816082
   PubMed Web of Science ®Google Scholar
• Olesen JB, Lip GY, Kamper AL, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367(7):625–635. doi: 10.1056/NEJMoa1105594
   PubMed Web of Science ®Google Scholar
• Magnocavallo M, Bellasi A, Mariani MV, et al. Thromboembolic and bleeding risk in atrial fibrillation patients with chronic kidney disease: role of anticoagulation therapy. J Clin Med. 2020;10(1):83. doi: 10.3390/jcm10010083
   PubMed Web of Science ®Google Scholar
• Potpara TS, Ferro CJ, Lip GYH. Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction. Nat Rev Nephrol. 2018;14(5):337–351. doi: 10.1038/nrneph.2018.19
   PubMed Web of Science ®Google Scholar
• Aursulesei V, Costache II. Anticoagulation in chronic kidney disease: from guidelines to clinical practice. Clin Cardiol. 2019;42(8):774–782. doi: 10.1002/clc.23196
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962. doi: 10.1016/S0140-6736(13)62343-0
   PubMed Web of Science ®Google Scholar
• Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018;154(5):1121–1201. doi: 10.1016/j.chest.2018.07.040
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm society. J Am Coll Cardiol. 2019;74(1):104–132. doi: 10.1016/j.jacc.2019.01.011
   PubMed Web of Science ®Google Scholar
• Fanola CL, Mooney D, Cowan AJ, et al. Incidence of severe renal dysfunction among individuals taking warfarin and implications for non-vitamin K oral anticoagulants. Am Heart J. 2017;184:150–155. doi: 10.1016/j.ahj.2016.08.017
   PubMed Web of Science ®Google Scholar
• Chen X, Liu Y, Furukawa N, et al. A novel vitamin K derived anticoagulant tolerant to genetic variations of vitamin K epoxide reductase. J Thromb Haemost. 2021;19(3):689–700. doi: 10.1111/jth.15209
   PubMed Web of Science ®Google Scholar
• Schein JR, White CM, Nelson WW, et al. Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences. Thromb J. 2016;14(1):14. doi: 10.1186/s12959-016-0088-y
   PubMedGoogle Scholar
• Rennenberg RJ, van Varik BJ, Schurgers LJ, et al. Chronic coumarin treatment is associated with increased extracoronary arterial calcification in humans. Blood. 2010;115(24):5121–5123. doi: 10.1182/blood-2010-01-264598
   PubMed Web of Science ®Google Scholar
• Hasific S, Ovrehus KA, Gerke O, et al. Extent of arterial calcification by conventional vitamin K antagonist treatment. PLoS One. 2020;15(10):e0241450. doi: 10.1371/journal.pone.0241450
   PubMed Web of Science ®Google Scholar
• Di Lullo L, Tripepi G, Ronco C, et al. Cardiac valve calcification and use of anticoagulants: preliminary observation of a potentially modifiable risk factor. Int J Cardiol. 2019;278:243–249. doi: 10.1016/j.ijcard.2018.11.119
   PubMed Web of Science ®Google Scholar
• Sonderskov PS, Lindholt JS, Hallas J, et al. Association of aortic valve calcification and vitamin K antagonist treatment. Eur Heart J Cardiovasc Imaging. 2020;21(7):718–724. doi: 10.1093/ehjci/jeaa065
   PubMed Web of Science ®Google Scholar
• Wei FF, Trenson S, Verhamme P, et al. Vitamin K-Dependent matrix Gla Protein as multifaceted protector of vascular and tissue integrity. Hypertension. 2019;73(6):1160–1169. doi: 10.1161/HYPERTENSIONAHA.119.12412
   PubMed Web of Science ®Google Scholar
• Townsend RR. Arterial stiffness in CKD: a review. Am J Kidney Dis. 2019;73(2):240–247. doi: 10.1053/j.ajkd.2018.04.005
   PubMed Web of Science ®Google Scholar
• Brodsky SV, Satoskar A, Chen J, et al. Acute kidney injury during warfarin therapy associated with obstructive tubular red blood cell casts: a report of 9 cases. Am J Kidney Dis. 2009;54(6):1121–1126. doi: 10.1053/j.ajkd.2009.04.024
   PubMed Web of Science ®Google Scholar
• Wheeler DS, Giugliano RP, Rangaswami J. Anticoagulation-related nephropathy. J Thromb Haemost. 2016;14(3):461–467. doi: 10.1111/jth.13229
   PubMed Web of Science ®Google Scholar
• Brodsky S, Eikelboom J, Hebert LA. Anticoagulant-Related Nephropathy. J Am Soc Nephrol. 2018;29(12):2787–2793. doi: 10.1681/ASN.2018070741
   PubMed Web of Science ®Google Scholar
• Brodsky SV, Nadasdy T, Rovin BH, et al. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int. 2011;80(2):181–189. doi: 10.1038/ki.2011.44
   PubMed Web of Science ®Google Scholar
• Piran S, Traquair H, Chan N, et al. Incidence and risk factors for acute kidney injury in patients with excessive anticoagulation on warfarin: a retrospective study. J Thromb Thrombolysis. 2018;45(4):557–561. doi: 10.1007/s11239-018-1626-1
   PubMed Web of Science ®Google Scholar
• de Aquino Moura KB, Behrens PMP, Pirolli R, et al. Anticoagulant-related nephropathy: systematic review and meta-analysis. Clin Kidney J. 2019;12(3):400–407. doi: 10.1093/ckj/sfy133
   PubMed Web of Science ®Google Scholar
• Armentaro G, D’Arrigo G, Bo M, et al. Medium-term and long-term renal function changes with direct oral anticoagulants in elderly patients with atrial fibrillation. Front Pharmacol. 2023 Jul 4;14:1210560. doi: 10.3389/fphar.2023.1210560
   PubMed Web of Science ®Google Scholar
• Pastori D, Ettorre E, Lip GYH, et al. Association of different oral anticoagulants use with renal function worsening in patients with atrial fibrillation: a multicentre cohort study. Br J Clin Pharmacol. 2020 Dec;86(12):2455–2463. doi: 10.1111/bcp.14350
   PubMed Web of Science ®Google Scholar
• An JN, Ahn SY, Yoon CH, et al. The occurrence of warfarin-related nephropathy and effects on renal and patient outcomes in Korean patients. PLoS One. 2013;8(4):e57661. doi: 10.1371/journal.pone.0057661
   PubMed Web of Science ®Google Scholar
• Lim AK, Campbell DA. Haematuria and acute kidney injury in elderly patients admitted to hospital with supratherapeutic warfarin anticoagulation. Int Urol Nephrol. 2013;45(2):561–570. doi: 10.1007/s11255-012-0364-0
   PubMed Web of Science ®Google Scholar
• Brodsky SV, Collins M, Park E, et al. Warfarin therapy that results in an International Normalization Ratio above the therapeutic range is associated with accelerated progression of chronic kidney disease. Nephron Clin Pract. 2010;115(2):c142–6. doi: 10.1159/000312877
   PubMedGoogle Scholar
• Moreno JA, Sevillano A, Gutierrez E, et al. Glomerular hematuria: cause or consequence of renal inflammation? Int J Mol Sci. 2019;20(9):2205. doi: 10.3390/ijms20092205
   PubMed Web of Science ®Google Scholar
• Brodsky SV, Mhaskar NS, Thiruveedi S, et al. Acute kidney injury aggravated by treatment initiation with apixaban: another twist of anticoagulant-related nephropathy. Kidney Res Clin Pract. 2017;36(4):387–392. doi: 10.23876/j.krcp.2017.36.4.387
   PubMed Web of Science ®Google Scholar
• Roldan V, Marin F, Fernandez H, et al. Renal impairment in a “real-life” cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). Am J Cardiol. 2013;111(8):1159–1164. doi: 10.1016/j.amjcard.2012.12.045
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151. doi: 10.1056/NEJMoa0905561
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806–817. doi: 10.1056/NEJMoa1007432
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992. doi: 10.1056/NEJMoa1107039
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891. doi: 10.1056/NEJMoa1009638
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–2104. doi: 10.1056/NEJMoa1310907
   PubMed Web of Science ®Google Scholar
• Huisman MV, Lip GY, Diener HC, et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost. 2012;107(5):838–847. doi: 10.1160/TH11-10-0718
   PubMed Web of Science ®Google Scholar
• Gui YY, Zou S, Yang WL, et al. The impact of renal function on efficacy and safety of new oral anticoagulant in atrial fibrillation patients: a systemic review and meta-analysis. Medicine (Baltimore). 2019;98(48):e18205. doi: 10.1097/MD.0000000000018205
   PubMed Web of Science ®Google Scholar
• Buckley LF, Rybak E, Aldemerdash A, et al. Direct oral anticoagulants in patients with atrial fibrillation and renal impairment, extremes in weight, or advanced age. Clin Cardiol. 2017;40(1):46–52. doi: 10.1002/clc.22591
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Eikelboom J, Dorian P, et al. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (explore-Xa). Eur Heart J. 2013;34(20):1498–1505. doi: 10.1093/eurheartj/eht039
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm society in collaboration with the society of thoracic surgeons. Circulation. 2019;140(2):e125–e51. doi: 10.1161/CIR.0000000000000665
   PubMed Web of Science ®Google Scholar
• Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–1676. doi: 10.1093/europace/euab065
   PubMed Web of Science ®Google Scholar
• Chan YH, Yeh YH, See LC, et al. Acute kidney injury in asians with atrial fibrillation treated with dabigatran or warfarin. J Am Coll Cardiol. 2016;68(21):2272–2283. doi: 10.1016/j.jacc.2016.08.063
   PubMed Web of Science ®Google Scholar
• Hijazi Z, Hohnloser SH, Andersson U, et al. Efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation in relation to renal function over time: insights from the ARISTOTLE randomized clinical trial. JAMA Cardiol. 2016;1(4):451–460. doi: 10.1001/jamacardio.2016.1170
   PubMed Web of Science ®Google Scholar
• Fordyce CB, Hellkamp AS, Lokhnygina Y, et al. On-treatment outcomes in patients with worsening renal function with rivaroxaban compared with warfarin: insights from ROCKET AF. Circulation. 2016;134(1):37–47. doi: 10.1161/CIRCULATIONAHA.116.021890
   PubMed Web of Science ®Google Scholar
• Yao X, Tangri N, Gersh BJ, et al. Renal outcomes in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2017;70(21):2621–2632. doi: 10.1016/j.jacc.2017.09.1087
   PubMed Web of Science ®Google Scholar
• Bohm M, Ezekowitz MD, Connolly SJ, et al. Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY trial. J Am Coll Cardiol. 2015;65(23):2481–2493. doi: 10.1016/j.jacc.2015.03.577
   PubMed Web of Science ®Google Scholar
• Ryan M, Ware K, Qamri Z, et al. Warfarin-related nephropathy is the tip of the iceberg: direct thrombin inhibitor dabigatran induces glomerular hemorrhage with acute kidney injury in rats. Nephrol Dial Transplant. 2014;29(12):2228–2234. doi: 10.1093/ndt/gft380
   PubMed Web of Science ®Google Scholar
• Diener HC, Halperin JL, Fox K, et al. Stroke prevention with rivaroxaban in higher-risk populations with atrial fibrillation. Int J Clin Pract. 2015;69(7):743–756. doi: 10.1111/ijcp.12631
   PubMed Web of Science ®Google Scholar
• Ichikawa H, Shimada M, Narita M, et al. Rivaroxaban, a direct factor Xa inhibitor, ameliorates hypertensive renal damage through inhibition of the inflammatory response mediated by protease-activated receptor pathway. J Am Heart Assoc. 2019;8(8):e012195. doi: 10.1161/JAHA.119.012195
   PubMed Web of Science ®Google Scholar
• Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330–1393. doi: 10.1093/eurheartj/ehy136
   PubMed Web of Science ®Google Scholar
• Vaitsiakhovich T, Coleman CI, Kleinjung F, et al. Worsening of kidney function in patients with atrial fibrillation and chronic kidney disease: evidence from the real-world CALLIPER study. Curr Med Res Opin. 2022;38(6):937–945. doi: 10.1080/03007995.2022.2061705
   PubMed Web of Science ®Google Scholar
• Inohara T, Holmes DN, Pieper K, et al. Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation. Heart. 2020;106(5):358–364. doi: 10.1136/heartjnl-2019-315792
   PubMed Web of Science ®Google Scholar
• Wetmore JB, Yan H, Herzog CA, et al. CKD progression in Medicare beneficiaries with nonvalvular atrial fibrillation treated with apixaban versus warfarin. Am J Kidney Dis. 2021;78(2):180–189. doi: 10.1053/j.ajkd.2020.12.004
   PubMed Web of Science ®Google Scholar
• Turpie AG, Kreutz R, Llau J, et al. Management consensus guidance for the use of rivaroxaban–an oral, direct factor Xa inhibitor. Thromb Haemost. 2012;108(5):876–886. doi: 10.1160/TH12-03-0209
   PubMed Web of Science ®Google Scholar
• Noseworthy PA, Yao X, Abraham NS, et al. Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation. Chest. 2016;150(6):1302–1312. doi: 10.1016/j.chest.2016.07.013
   PubMed Web of Science ®Google Scholar
• Kreutz R, Deray G, Floege J, et al. Rationale and design of XARENO: XA inhibition in RENal patients with non-valvular atrial fibrillation Observational Registry. Kardiol Pol. 2021;79(11):1265–1267. doi: 10.33963/KP.a2021.0134
   PubMed Web of Science ®Google Scholar
• Petzold T, Thienel M, Dannenberg L, et al. Rivaroxaban reduces arterial thrombosis by inhibition of FXa-driven platelet activation via protease activated receptor-1. Circ Res. 2020;126(4):486–500. doi: 10.1161/CIRCRESAHA.119.315099
   PubMed Web of Science ®Google Scholar
• Hernandez AV, Bradley G, Khan M, et al. Rivaroxaban vs. warfarin and renal outcomes in non-valvular atrial fibrillation patients with diabetes. Eur Heart J Qual Care Clin Outcomes. 2020;6(4):301–307. doi: 10.1093/ehjqcco/qcz047
   PubMed Web of Science ®Google Scholar
• Coleman CI, Kreutz R, Sood N, et al. Rivaroxaban’s impact on renal decline in patients with nonvalvular atrial fibrillation: a US MarketScan claims database analysis. Clin Appl Thromb Hemost. 2019;25:1076029619868535. doi: 10.1177/1076029619868535
   Web of Science ®Google Scholar